摘要
目的探究金水宝胶囊对慢性阻塞性肺疾病(COPD)患者急性加重住院风险的影响。方法选取2023年6月至2024年3月上饶市立医院收治的60例COPD患者作为研究对象,根据治疗方式不同分为对照组和研究组,各30例。对照组进行常规治疗(戒烟、呼吸肌锻炼、针对低氧血症患者给予吸入药物治疗);研究组在对照组基础上加用金水宝胶囊。比较两组患者治疗前和治疗后6个月肺功能指标[最大呼气流量(PEF)、用力肺活量(FVC)、第一秒用力呼气量(FEV_(1))、FEV_(1)/FVC]、炎症因子[白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)]水平、改良版英国医学研究委员会呼吸困难问卷(mMRC)评分、6 min步行试验距离、生活质量(呼吸症状、活动能力、疾病影响)评分,急性加重次数及不良反应发生情况。结果治疗后,研究组患者PEF、FVC、FEV_(1)、FEV_(1)/FVC高于对照组[(3.32±0.35)L/s比(3.11±0.29)L/s、(3.18±0.31)L比(2.91±0.28)L、(2.19±0.49)L比(1.88±0.38)L、(58.95±5.79)%比(63.03±6.17)%](P<0.05或P<0.01);研究组IL-6、TNF-α水平低于对照组[(36.0±4.0)ng/L比(39.0±4.3)ng/L、(33.0±2.4)ng/L比(40.7±3.7)ng/L](P<0.01);研究组mMRC评分低于对照组[(0.88±0.09)分比(1.09±0.21)分](P<0.01),6 min步行试验距离大于对照组[(350±35)m比(333±30)m](P<0.05);研究组呼吸症状、活动能力、疾病影响评分低于对照组[(39.7±3.0)分比(42.0±4.9)分、(52.6±5.0)分比(60.3±5.8)分、(43.7±4.1)分比(47.5±4.6)分](P<0.05或P<0.01)。治疗后,研究组患者急性加重次数少于对照组[(1.5±0.3)次比(2.3±0.3)次](t=10.169,P<0.001)。两组患者不良反应发生率比较差异无统计学意义(P>0.05)。结论金水宝胶囊可显著改善COPD患者肺功能、降低炎症因子水平、提高运动耐力和生活质量,并减少急性加重次数,同时具有良好的安全性,适合作为COPD综合治疗的有效辅助方案。
Objective To explore the effect of Jinshuibao capsules on the risk of acute exacerbation hospitalization for patients with chronic obstructive pulmonary disease(COPD).Methods Sixty COPD patients admitted to Shangrao Municipal Hospital from Jun.2023 to Mar.2024 were included as the study subjects,and were divided into a control group and a study group according to different treatment methods,with 30 cases in each group.The control group received conventional treatment(smoking cessation,respiratory muscle exercise,and inhalation drug therapy for patients with hypoxemia).The study group added Jinshuibao capsules on the basis of the control group.The pulmonary function indicators[peak expiratory flow(PEF),forced vital capacity(FVC),forced expiratory volume in first second(FEV_(1)),FEV_(1)/FVC],inflammatory factors[interleukin-6(IL-6),tumor necrosis factor-α(TNF-α)],modified Medical Research Council dyspnea scale(mMRC)score,six-minute walk test distance and the score of quality of life(respiratory symptoms,activity ability,disease impact)were compared between the two groups before treatment and 6 months after treatment,as well as the number of acute exacerbations and the occurrence of adverse reactions.Results After treatment,the patients in the study group showed higher PEF,FVC,FEV_(1) and FEV_(1)/FVC compared to the control group[(3.32±0.35)L/s vs(3.11±0.29)L/s,(3.18±0.31)L vs(2.91±0.28)L,(2.19±0.49)L vs(1.88±0.38)L,(58.95±5.79)%vs(63.03±6.17)%](P<0.05 or P<0.01).The IL-6 and TNF-αlevels in the study group were lower than those in the control group[(36.0±4.0)ng/L vs(39.0±4.3)ng/L,(33.0±2.4)ng/L vs(40.7±3.7)ng/L](P<0.01).The mMRC score in the study group was lower than that in the control group(0.88±0.09 vs 1.09±0.21)(P<0.01),and the six-minute walk test distance was greater than that in the control group[(350±35)m vs(333±30)m](P<0.05).The study group also had lower scores for respiratory symptoms,physical activity,and disease impact compared to the control group(39.7±3.0 vs 42.0±4.9,52.6±5.0 vs 60.3±5.8,43.7±4.1 vs 47.5±4.6)(P<0.05 or P<0.01).After treatment,the number of acute exacerbations in the study group was less than that in the control group[(1.5±0.3)times vs(2.3±0.3)times](t=10.169,P<0.001).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Jinshuibao capsules can significantly improve lung function,reduce inflammation factor levels,enhance exercise tolerance and quality of life,and decrease the frequency of acute exacerbations in COPD patients.Additionally,they have good safety profiles,making them a suitable and effective adjunct therapy for the comprehensive treatment of COPD.
作者
吴俊文
夏颖
孙攀博
WU Junwen;XIA Ying;SUN Panbo(Department of Respiratory and Critical Care Medicine,Shangrao Municipal Hospital,Shangrao 334000,China)
出处
《医学综述》
2025年第15期1910-1914,1920,共6页
Medical Recapitulate
基金
上饶市科技计划一般项目(20241CZDX46)。
关键词
慢性阻塞性肺疾病
金水宝胶囊
急性加重
住院风险
Chronic obstructive pulmonary disease
Jinshuibao capsules
Acute exacerbation
Hospitalization risk
